Cytori Therapeutics, Inc. (NASDAQ: CYTX) presented data from two preclinical studies funded through its contract with the United States Biomedical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE